<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03442985</url>
  </required_header>
  <id_info>
    <org_study_id>PVO-2A-201</org_study_id>
    <secondary_id>2017-002751-28</secondary_id>
    <nct_id>NCT03442985</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Palovarotene for the Treatment of MO</brief_title>
  <acronym>MO-Ped</acronym>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clementia Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study comparing the safety and
      efficacy of 2 dosage regimens of palovarotene versus placebo in preventing disease
      progression in pediatric subjects with multiple osteochondromas (MO).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple osteochondromas is a rare condition where children develop multiple benign
      cartilage-capped bony tumors called osteochondromas on bones throughout the body, resulting
      in pain, deformity, limb length discrepancy, disability, and eventually arthritis and
      possible malignancy. The primary objective is to compare the efficacy of two dosage regimens
      of palovarotene with placebo to prevent the formation of new osteochondromas in pediatric MO
      subjects with exostosin 1 or exostosin 2 gene mutations. Osteochondroma formation will be
      assessed by whole body magnetic resonance imaging (MRI). Secondary efficacy objectives are to
      compare the effect of palovarotene on the volume of osteochondromas as assessed by MRI; and
      on the annualized rate of new or worsening deformities and MO-related surgeries. The overall
      safety of palovarotene and the effects of palovarotene on linear growth, bone growth plates,
      bone mineral density, quality of life, and pain due to osteochondromas will also be studied.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 20, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, randomized, double-blind, placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized rate of new osteochondromas</measure>
    <time_frame>Month 24</time_frame>
    <description>The annualized rate of new osteochondromas as assessed by whole body magnetic resonance imaging (MRI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total volume of osteochondromas</measure>
    <time_frame>Months 12 and 24/end-of-treatment (EOT)</time_frame>
    <description>The change from baseline in the total volume of osteochondromas as assessed by whole body MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of new or worsening deformities</measure>
    <time_frame>Months 12 and 24/EOT</time_frame>
    <description>The annualized rate of new or worsening deformities as assessed by radiographic imaging of both upper and lower limbs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of MO-related surgeries</measure>
    <time_frame>Months 12 and 24/EOT</time_frame>
    <description>The annualized rate of MO-related surgeries. Surgeries include surgical excisions of a symptomatic osteochondroma and surgical procedures to correct a joint deformities or functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palovarotene area under the concentration-time curve (AUC)</measure>
    <time_frame>Month 1</time_frame>
    <description>Determination of AUC at steady-state assessed during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palatability</measure>
    <time_frame>Day 1 and Month 1</time_frame>
    <description>The palatability of the drug product versus placebo when sprinkled onto specific foods as assessed by a five-point hedonic face scale.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety of Palovarotene: Monitoring of adverse events</measure>
    <time_frame>Study Day 1; and from Months 1 to 30/ET at every subject contact</time_frame>
    <description>Monitoring of adverse events.</description>
  </other_outcome>
  <other_outcome>
    <measure>Volume of osteochondroma cartilage cap</measure>
    <time_frame>Months 12 and 24</time_frame>
    <description>Change from baseline in the total volume of cartilage cap of osteochondromas as assessed by whole body MRI</description>
  </other_outcome>
  <other_outcome>
    <measure>Annualized rate of new or worsening functional limitations</measure>
    <time_frame>Months 12 and 24/EOT</time_frame>
    <description>The annualized rate of new or worsening functional limitations. Functional limitations are defined as restrictions in joint range of motion.</description>
  </other_outcome>
  <other_outcome>
    <measure>PedsQL</measure>
    <time_frame>Months 6, 12, 18, and 24/EOT</time_frame>
    <description>The Pediatric Quality of Life Inventory (PedsQL, version 4.0) questionnaire to assess quality of life.</description>
  </other_outcome>
  <other_outcome>
    <measure>PROMIS Global Health Scale</measure>
    <time_frame>Months 6, 12, 18, and 24/EOT</time_frame>
    <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference pediatric item bank to assess the effect of pain on daily activities.</description>
  </other_outcome>
  <other_outcome>
    <measure>FPS-R</measure>
    <time_frame>Months 6, 12, 18, and 24/EOT</time_frame>
    <description>The Faces Pain Scale - Revised (FPS-R) to assess pain intensity.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Exostoses, Multiple Hereditary</condition>
  <arm_group>
    <arm_group_label>Palovarotene 2.5 mg daily regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Palovarotene 5.0 mg daily regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo regimen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palovarotene 2.5 mg</intervention_name>
    <description>Subjects will receive a weight-adjusted dose equivalent of 2.5 mg palovarotene, once daily, for up to 24 months.</description>
    <arm_group_label>Palovarotene 2.5 mg daily regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palovarotene 5.0 mg</intervention_name>
    <description>Subjects will receive a weight-adjusted dose equivalent of 5.0 mg palovarotene, once daily, for up to 24 months.</description>
    <arm_group_label>Palovarotene 5.0 mg daily regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo, once daily, for up to 24 months.</description>
    <arm_group_label>Placebo regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Written, signed, and dated informed subject/parent consent and age-appropriate assent
             (performed according to local regulations).

          -  A clinical diagnosis of MO with disease-causing exostosin 1 or 2 gene mutations.

          -  Male or female from 2 to 14 years of age.

          -  Female subjects must be premenarchal at screening.

          -  A bone age at screening of 14 years or less.

          -  Symptomatic MO, defined as five or more clinically-evident osteochondromas and a new
             or enlarged osteochondroma that occurred in the preceding 12 months, five or more
             clinically-evident osteochondromas and the presence of a painful osteochondroma, a
             skeletal deformity, a joint limitation, or prior surgery for a MO-related
             complication.

          -  The ability to undergo whole body MRI with or without sedation/general anesthesia.

          -  Use of two effective methods of birth control during treatment, and for 1 month after
             treatment discontinuation, unless committed to true abstinence from heterosexual sex.
             Sexually active females of child-bearing potential must also agree to start effective
             methods of birth control at screening.

        Key Exclusion Criteria:

          -  Weight under 10 kg.

          -  Other syndromic conditions such as Langer-Giedion or Potocki-Shaffer.

          -  Any subject with neurologic signs suggestive of spinal cord impingement.

          -  Concomitant medications that are strong inhibitors or inducers of cytochrome P450 3A4
             activity.

          -  Amylase or lipase &gt;2 times the above the upper limit of normal (&gt;2×ULN) or with a
             history of chronic pancreatitis.

          -  Elevated aspartate aminotransferase or alanine aminotransferase above 2.5×ULN.

          -  Any surgical implant that is contraindicated for MRI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Orthopaedic Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children - Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California-San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Paley Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>330407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - PPDS</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shriners Hospitals for Children - Portland</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia (CHOP)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19410-4160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Children's Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Sainte-Justine</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children - Canada</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital universitaire Necker - Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital des Enfants, CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituti Ortopedici Rizzoli</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aiti</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLVG locatie Oost</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pediátrico de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-602</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty Hospital</name>
      <address>
        <city>Bornova</city>
        <state>Izmir</state>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bezmialem Vakif University Medical Faculty Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evelina London Children's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Childrens Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal National Orthopaedic Hospital</name>
      <address>
        <city>Stanmore</city>
        <zip>HA7 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mhecoalition.org/</url>
    <description>MHE Coalition</description>
  </link>
  <link>
    <url>http://www.mherf.org/</url>
    <description>MHE Research Foundation</description>
  </link>
  <reference>
    <citation>Inubushi T, Lemire I, Irie F, Yamaguchi Y. Palovarotene Inhibits Osteochondroma Formation in a Mouse Model of Multiple Hereditary Exostoses. J Bone Miner Res. 2018 Apr;33(4):658-666. doi: 10.1002/jbmr.3341. Epub 2017 Nov 30.</citation>
    <PMID>29120519</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>February 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple osteochondromas</keyword>
  <keyword>Osteochondroma</keyword>
  <keyword>Palovarotene</keyword>
  <keyword>Hereditary multiple exostoses</keyword>
  <keyword>HME</keyword>
  <keyword>MO</keyword>
  <keyword>Retinoic acid receptor gamma agonist</keyword>
  <keyword>Retinoic acid receptor agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteochondroma</mesh_term>
    <mesh_term>Exostoses, Multiple Hereditary</mesh_term>
    <mesh_term>Osteochondromatosis</mesh_term>
    <mesh_term>Exostoses</mesh_term>
    <mesh_term>Osteophyte</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

